COMPARE · Data as of August 21, 2026
BHC vs INDV
Verdict: Side-by-side breakdown using the Bull Rankings model. BHC scored 71.3, INDV scored 63.0 — BHC leads.
Compare another set
BHC
Bausch Health Companies Inc.
71.3
$6.44 · $2.4B
fundamentals as of
Score gap
8.3
BHC leads
INDV
Indivior Pharmaceuticals, Inc.
63
$36.87 · $4.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestBHC0.2x
- Fastest growthINDV+13.5%
- Highest qualityBHC63 / 100
- Largest discount to fair valueBHC-86%
Side by side · every name on one set of axes
Growth against the P/S multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
BHC
stronger →← stronger
INDV
63
Qualityreturns · margins · balance sheet
50
64
Growthrevenue & earnings expansion
87
90
Valuevaluation vs sector peers
57
BHC is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BHC
INDV
$1.4bC+
FCF
-$111mF
+10.1%B
Rev
+13.5%B+
0.2xA
P/S
3.3xB+
0.01A
PEG
1.26B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BHC
INDV
86% below
Price vs fair valuelower is cheaper
—
decline
Growth the price implies10-yr FCF · lower = less priced in
—
+706%
1-yr DCF upside
—
+625%
5-yr DCF upside
—
+526%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BHC
INDV
Why this score
- Buying back stock
The companies
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.4b. 19% off the 52-week high of $8.00. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $7.50 (implying +16% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
INDVIndivior Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $4.4b. 14% off the 52-week high of $42.81. Revenue growing +13%, comfortably above the S&P median. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $49.00 (implying +33% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$111m) — capital raises or debt issuance likely required; dilution / leverage risk. ROE -171% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BHC and INDV diverge
On the headline score the gap is 8.3 points in favor of BHC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueBHC 90.4 · INDV 57.5BHC +32.9
- GrowthBHC 63.7 · INDV 87.2INDV +23.5
- QualityBHC 62.9 · INDV 49.9BHC +13.0
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.